Please login to the form below

Not currently logged in
Email:
Password:

The Harmony Alliance gathers to battle blood cancer

Uses its big data platform to analyse the disease

blood cellsAt the 2nd general assembly based in Berlin, Germany last week, 120 representatives from the Innovative Medicines Initiative’s (IMI) Harmony Alliance all gathered to discuss achievements and objectives surrounding blood cancer.

The alliance, which brings together 51 partners and key stakeholders from eleven European countries, uses its big data platform to better understand blood cancer and contribute to improving targeted therapies.

Michel Van Speybroeck, director of data sciences, Janssen, said: “Public and private partners are bringing together their best people, data and knowledge to solve key questions on haematological cancers.

“These challenges can only be met by applying the most advanced technology and it’s wonderful to see from the front-line how this is being shaped by the Harmony Alliance.”

The alliance aims to offer an ethical and legal framework on the use of medical data, using its new platform for analysis and defining “standard sets of outcomes”.

Article by
Gemma Jones

30th October 2017

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics